Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma - A Southwest Oncology Group study

Ralph B. Vance, John J. Crowley, John S. Macdonald, Frederick R. Ahmann

Research output: Contribution to journalArticle

Abstract

Forty-five patients with non-small cell lung cancer were treated in a phase II trial with menogaril 200 mg/m2 IV every twenty-eight days by a one-hour infusion. One partial response was noted while twenty-two patients had stable disease (51 %). Progressive disease was noted in the remaining twenty-two patients. There was one fatal complication due to pancytopenia and pneumonia. Otherwise, the drug was reasonably well tolerated. At this dosage and schedule, menogaril has no substantial anti-tumor activity for patients with non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)73-75
Number of pages3
JournalInvestigational New Drugs
Volume9
Issue number1
DOIs
StatePublished - Feb 1 1991

Keywords

  • menogaril
  • non-small cell lung carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma - A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this